source
- Celldex halts skin disease program after barzolvolimab fails phase 2 trialCelldex Therapeutics announced it is discontinuing development of its anti‑KIT antibody barzolvolimab for chronic skin disorders after the drug failed to meet its primary endpoint in a phase 2 stud…
- MDCG: Only manufacturers should assign UDI-DIsThe European Commission's Medical Device Coordination Group (MDCG) says unique device identifiers and device identifiers (UDI-DI) codes used between manufacturers and distributors need to be better…